Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA new revision label was added: Revision: v3.6.4, replacing Revision: v3.6.3. This indicates a minor version update to the page's documentation.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check40 days agoChange DetectedThe page now displays revision tag v3.6.3, replacing v3.6.0, indicating a small update to the page's documentation/versioning rather than changes to study details or visible content.SummaryDifference0.0%

- Check47 days agoChange DetectedA new publication entry has been added to the Publications section, listing authors and bibliographic details for a CIDP-related genetic study.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page now indicates that enrollment is closed, and new guidance sections related to reading the study record and joining the study have been added. A formatting change to the Intervention/Treatment label and a revision note were also applied.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page shows Revision: v3.5.4, replacing the previous v3.5.3. This indicates a minor internal update to the trial entry rather than changes to the study details or results.SummaryDifference0.0%

- Check97 days agoChange DetectedTaiwan enrollment location updated: Taoyuan District, Taiwan was removed and Taoyuan, Taiwan was added to the study's locations.SummaryDifference0.0%

Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.